BOPA member published in the Journal of Oncology Pharmacy Practice
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions
Immunotherapy is an evolving therapeutic modality which confers a range of clinical advantages in the treatment of malignant disease. Oncology pharmacists, pharmacy technicians and assistants are key members of the multidisciplinary health care team caring for patients receiving immunotherapy. The International Society of Oncology Pharmacy Practitioners (ISOPP) has developed a position statement to provide guidance to pharmacy professionals working in this field and to promote the role that pharmacy staff have to offer in providing safe and effective treatment with immunotherapy.
Four key recommendations were identified:
1) participation as an integrated, collaborative member of the MHT
1) provision of education and training for patients, students, residents, fellows and other members of the MHT
3) involvement in clinical governance to optimise the use of immune checkpoint inhibitors
4) involvement in research and development in the field of immunotherapy.
Read the full article here: https://journals.sagepub.com/doi/10.1177/10781552221090199
